

Number at risk

Canagliflozin 7990

Placebo 6541

7053

5749

6227

4904

3260


2045


2036

1028

— Canagliflozin

— Placebo







Number at risk	7990	7053	6227	3260	2036
Canagliflozin					
Placebo	6541	5749	4904	2045	1028


Study	Number of participants with event		Event rate per 1000 patient years		HR (95% CI)	P interaction
	Canagliflozin n/N	Placebo n/N	Canagliflozin	Placebo		
CANVAS	324/2886	137/1441	27.4	25.1	1.11 (0.91, 1.36)	0.18
CANVAS-R	34/2904	35/2903	6.2	6.5	0.95 (0.59, 1.53)	
CRENDENCE	175/2200	198/2197	35.8	42.6	0.85 (0.69, 1.04)	
Overall	533/7990	370/6541	24.0	23.9	0.97 (0.85, 1.11)	


0.5 1 2


Lower risk with canagliflozin Higher risk with canagliflozin






















Not to be included

